小细胞肺癌转移机制的研究进展

doi:10.3969/j.issn.1004-616x.2024.04.012

摘要/Abstract

摘要： 小细胞肺癌(SCLC)是恶性程度最高的肺癌亚型，具有分化程度低、倍增时间短、侵袭性强、早期易出现远处转移等生物学行为，临床预后极差。获得性耐药和远处转移是患者死亡的主要原因，深入研究SCLC转移机制有利于寻找潜在的治疗靶点，为药物研发提供新思路。受限于组织样本稀少及缺乏可靠的临床前模型，SCLC临床及基础研究进展缓慢。近年来，液态活检技术的进步及基因工程小鼠模型的建立为SCLC研究开展提供了新的工具，相关细胞及分子层面的研究结果亦为转移机制提供了不同见解。本文就SCLC转移机制的研究进展进行综述，以探讨从多个方面阻断肿瘤细胞发生转移的方法，为SCLC的治疗提供新视角。

关键词: 小细胞肺癌, 临床前模型, 转移机制, 研究进展

中图分类号:

R734.2

王莹, 褚洪迁, 刘艳霞, 张同梅. 小细胞肺癌转移机制的研究进展[J]. 癌变·畸变·突变, 2024, 36(4): 315-319.

参考文献

[1] LIANG J, GUAN X, BAO G, et al. Molecular subtyping of small cell lung cancer[J]. Semin Cancer Biol, 2022, 86(pt 2): 450-462.
[2] A plan of attack for deadly cancers[J]. Cancer Discov, 2014, 4(9): 980.
[3] TARIQ S, KIM S Y, MONTEIRO DE OLIVEIRA NOVAES J, et al. Update 2021: management of small cell lung cancer[J]. Lung, 2021, 199(6): 579-587.
[4] SIMPSON K L, STONEY R, FRESE K K, et al. A biobank of small cell lung cancer CDX models elucidates inter- and intratumoral phenotypic heterogeneity[J]. Nat Cancer, 2020, 1(4): 437-451.
[5] DRAPKIN B J, GEORGE J, CHRISTENSEN C L, et al. Genomic and functional fidelity of small cell lung cancer patient-derived xenografts [J]. Cancer Discov, 2018, 8(5): 600-615.
[6] STEWART C A, GAY C M, XI Y X, et al. Single-cell analyses reveal increased intratumoral heterogeneity after the onset of therapy resistance in small-cell lung cancer[J]. Nat Cancer, 2020, 1: 423-436.
[7] RUDIN C M, BRAMBILLA E, FAIVRE-FINN C, et al. Small-cell lung cancer[J]. Nat Rev Dis Primers, 2021, 7(1): 3.
[8] RUDIN C M, POIRIER J T, BYERS L A, et al. Molecular subtypes of small cell lung cancer: a synthesis of human and mouse model data[J]. Nat Rev Cancer, 2019, 19(5): 289-297.
[9] GAZDAR A F, SAVAGE T K, JOHNSON J E, et al. The comparative pathology of genetically engineered mouse models for neuroendocrine carcinomas of the lung[J]. J Thorac Oncol, 2015, 10(4): 553-564.
[10] CHOI S Y, CHO Y H, KIM D S, et al. Establishment and long-term expansion of small cell lung cancer patient-derived tumor organoids[J]. Int J Mol Sci, 2021, 22(3): 1349.
[11] PASTUSHENKO I, BLANPAIN C. EMT transition states during tumor progression and metastasis[J]. Trends Cell Biol, 2019, 29(3): 212-226.
[12] WANG Y, LIU Y X, ZHANG L N, et al. Vimentin expression in circulating tumor cells (CTCs) associated with liver metastases predicts poor progression-free survival in patients with advanced lung cancer[J]. J Cancer Res Clin Oncol, 2019, 145(12): 2911-2920.
[13] XU J F, LIU S L, YANG X P, et al. Paracrine HGF promotes EMT and mediates the effects of PSC on chemoresistance by activating c-Met/ PI3K/Akt signaling in pancreatic cancer in vitro[J]. Life Sci, 2020, 263: 118523.
[14] HUANG J L, CAO D D, SHA J, et al. DLL3 is regulated by LIN28B and miR-518d-5p and regulates cell proliferation, migration and chemotherapy response in advanced small cell lung cancer[J]. Biochem Biophys Res Commun, 2019, 514(3): 853-860.
[15] MESSARITAKIS I, NIKOLAOU M, KOINIS F, et al. Characterization of DLL3-positive circulating tumor cells (CTCs) in patients with small cell lung cancer (SCLC) and evaluation of their clinical relevance during front-line treatment[J]. Lung Cancer, 2019, 135: 33-39.
[16] FURUTA M, KIKUCHI H, SHOJI T, et al. DLL3 regulates the migration and invasion of small cell lung cancer by modulating Snail[J]. Cancer Sci, 2019, 110(5): 1599-1608.
[17] 周菁, 郭丽. DLL3沉默抑制小细胞肺癌细胞系H592的增殖和迁移[J]. 江苏大学学报: 医学版, 2020, 30(4): 330-335.
[18] GIFFIN M J, COOKE K, LOBENHOFER E K, et al. AMG 757, a half-life extended, DLL3-targeted bispecific T-cell engager, shows high potency and sensitivity in preclinical models of small-cell lung cancer[J]. Clin Cancer Res, 2021, 27(5): 1526-1537.
[19] SONG J M, IM J, NHO R S, et al. Hyaluronan-CD44/RHAMM interaction-dependent cell proliferation and survival in lung cancer cells [J]. Mol Carcinog, 2019, 58(3): 321-333.
[20] WANG Y, GUO Y, LIN H F, et al. Expression of CD44 in tumor tissue and serum of small cell lung cancer and its clinical prognostic significance[J]. Chin J Lung Cancer, 2021, 24(8): 583-590.
[21] ZHAO C, ZHANG Z Y, HU X S, et al. Hyaluronic acid correlates with bone metastasis and predicts poor prognosis in small-cell lung cancer patients[J]. Front Endocrinol, 2021, 12: 785192.
[22] JIN Y J, ZHAO Q Q, ZHU W K, et al. Identification of TAZ as the essential molecular switch in orchestrating SCLC phenotypic transition and metastasis[J]. Natl Sci Rev, 2022, 9(7): nwab232.
[23] ILHAN-MUTLU A, SIEHS C, BERGHOFF A S, et al. Expression profiling of angiogenesis-related genes in brain metastases of lung cancer and melanoma[J]. Tumour Biol, 2016, 37(1): 1173-1182.
[24] LI B, WANG C, ZHANG Y, et al. Elevated PLGF contributes to smallcell lung cancer brain metastasis[J]. Oncogene, 2013, 32(24): 2952- 2962.
[25] KWON M C, PROOST N, SONG J Y, et al. Paracrine signaling between tumor subclones of mouse SCLC: a critical role of ETS transcription factor Pea3 in facilitating metastasis[J]. Genes Dev, 2015, 29(15): 1587- 1592.
[26] DENNY S K, YANG D, CHUANG C H, et al. Nfib promotes metastasis through a widespread increase in chromatin accessibility[J]. Cell, 2016, 166(2): 328-342.
[27] SEMENOVA E A, KWON M C, MONKHORST K, et al. Transcription factor NFIB is a driver of small cell lung cancer progression in mice and marks metastatic disease in patients[J]. Cell Rep, 2016, 16(3): 631-643.
[28] WU N, JIA D S, IBRAHIM A H, et al. NFIB overexpression cooperates with Rb/p53 deletion to promote small cell lung cancer[J]. Oncotarget, 2016, 7(36): 57514-57524.
[29] YANG D, QU F F, CAI H C, et al. Axon-like protrusions promote small cell lung cancer migration and metastasis[J]. Elife, 2019, 8: e50616.
[30] LIU C N, YI J H, JIA J M. Diagnostic and prognostic nomograms for bone metastasis in small cell lung cancer[J]. J Int Med Res, 2021, 49(10): 3000605211050735.
[31] BÖTTGER F, SEMENOVA E A, SONG J Y, et al. Tumor heterogeneity underlies differential cisplatin sensitivity in mouse models of small-cell lung cancer[J]. Cell Rep, 2019, 27(11): 3345-3358.e4.
[32] HOU J M, KREBS M G, LANCASHIRE L, et al. Clinical significance and molecular characteristics of circulating tumor cells and circulating tumor microemboli in patients with small-cell lung cancer[J]. J Clin Oncol, 2012, 30(5): 525-532.
[33] LIM J S, IBASETA A, FISCHER M M, et al. Intratumoural heterogeneity generated by Notch signalling promotes small-cell lung cancer[J]. Nature, 2017, 545(7654): 360-364.
[34] BEST S A, HESS J B, SOUZA-FONSECA-GUIMARAES F, et al. Harnessing natural killer immunity in metastatic SCLC[J]. J Thorac Oncol, 2020, 15(9): 1507-1521.
[35] SIONOV R V, FRIDLENDER Z G, GRANOT Z. The multifaceted roles neutrophils play in the tumor microenvironment[J]. Cancer Microenviron, 2015, 8(3): 125-158.
[36] SZCZERBA B M, CASTRO-GINER F, VETTER M, et al. Neutrophils escort circulating tumour cells to enable cell cycle progression[J]. Nature, 2019, 566(7745): 553-557.
[37] ZHU H H, LIU Y T, FENG Y, et al. Circulating tumor cells (CTCs)/ circulating tumor endothelial cells (CTECs) and their subtypes in small cell lung cancer: Predictors for response and prognosis[J]. Thorac Cancer, 2021, 12(20): 2749-2757.
[38] WILLIAMSON S C, METCALF R L, TRAPANI F, et al. Vasculogenic mimicry in small cell lung cancer[J]. Nat Commun, 2016, 7: 13322.
[39] HEIDEMANN F, SCHILDT A, SCHMID K, et al. Selectins mediate small cell lung cancer systemic metastasis[J]. PLoS One, 2014, 9(4): e92327.
[40] ZHAO G X, GONG L Y, SU D, et al. Cullin5 deficiency promotes smallcell lung cancer metastasis by stabilizing integrin β1[J]. J Clin Invest, 2019, 129(3): 972-987.
[41] MA N Q, PANG H L, SHEN W W, et al. Downregulation of CXCR4 by SDF-KDEL in SBC-5 cells inhibits their migration in vitro and organ metastasis in vivo[J]. Int J Mol Med, 2015, 35(2): 425-432.